Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling

被引:34
|
作者
Park, Keun Ha [1 ]
Gu, Dong Ryun [1 ,2 ]
Jin, Su Hyun [2 ]
Yoon, Chi-Su [3 ,4 ]
Ko, Wonmin [3 ,4 ]
Kim, Youn Chul [3 ,4 ]
Lee, Seoung Hoon [1 ,2 ,5 ]
机构
[1] Wonkwang Univ, Coll Dent, Dept Oral Microbiol & Immunol, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea
[2] Wonkwang Univ, CMFR, Sch Med, Iksan 54538, Jeonbuk, South Korea
[3] Wonkwang Univ, Inst Pharmaceut Res & Dev, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[4] Wonkwang Univ, Standardized Mat Bank New Bot Drugs, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[5] Wonkwang Univ, Inst Biomat & Implant, Iksan 54538, Jeonbuk, South Korea
来源
AMERICAN JOURNAL OF CHINESE MEDICINE | 2017年 / 45卷 / 08期
关键词
Pueraria lobate; Puerariae radix; Osteoclast; NFATc1; PGC1; beta; CREB; Bone Disease; PREVENTS BONE LOSS; HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIALS; OVARIECTOMIZED MICE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RECEPTOR ACTIVATOR; SOY ISOFLAVONES; IN-VITRO; PHYTOESTROGENS;
D O I
10.1142/S0192415X17500938
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Puerariae radix, the dried root of Pueraria lobate Ohwi, is known to prevent bone loss in ovariectomized mice; however, the precise molecular mechanisms are not understood. In this study, we investigated the effects and underlying mechanisms of action of Puerariae radix extract (PRE) on receptor activator of NF-kappa B ligand (RANKL)-induced osteoclastogenesis. PRE dose-dependently inhibited osteoclast differentiation and formation, decreased the bone-resorbing activity of osteoclasts, and downregulated the expression of osteoclast differentiation marker genes. The expression of osteoclastogenic factors produced by PRE-treated osteoblasts such as RANKL, macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) was comparable to that of untreated (control) cells. However, the formation of osteoclasts via bone marrow cell and calvaria-derived osteoblast co-cultures was suppressed by PRE treatment. Therefore, the inhibitory effects of PRE on osteoclastogenesis clearly targeted osteoclasts, but not osteoblasts. PRE treatment considerably reduced RANKL-induced mitogen-activated protein kinases (MAPKs) activity, especially c-Jun N-terminal kinase, in osteoclast precursor cells. In addition, PRE markedly suppressed cAMP response element-binding protein (CREB) activation and the induction of peroxisome proliferator-activated receptor gamma coactivator 1 beta (PGC1 beta), which stimulate osteoclastogenesis - an effect that was not observed for puerarin and 17-beta estradiol. Finally, PRE treatment significantly repressed the expression of c-Fos and the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), which is a master transcription factor for osteoclastogenesis in vitro and in vivo. Overall, these results strongly suggest that PRE is an effective inhibitor of RANKL-induced osteoclastogenesis and may be a potent therapeutic agent for bone-related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.
引用
收藏
页码:1725 / 1744
页数:20
相关论文
共 50 条
  • [21] Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis
    Deepak, Vishwa
    Kruger, Marlena C.
    Joubert, Annie
    Coetzee, Magdalena
    BIOFACTORS, 2015, 41 (06) : 403 - 413
  • [22] Inhibitory Effect of Purpurogallin on Osteoclast Differentiation In Vitro through the Downregulation of c-Fos and NFATc1
    Kim, Kiryeong
    Kim, Tae Hoon
    Ihn, Hye Jung
    Kim, Jung Eun
    Choi, Je-Yong
    Shin, Hong-In
    Park, Eui Kyun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (02)
  • [23] Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling
    Xiao, Yu
    Li, Kai
    Wang, Ziyi
    Fu, Fangsheng
    Shao, Siyuan
    Song, Fangming
    Zhao, Jinmin
    Chen, Weiwei
    Liu, Qian
    Xu, Jiake
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (08) : 13959 - 13968
  • [24] Gleditsiae fructus regulates osteoclastogenesis by inhibiting the c-Fos/NFATc1 pathway and alleviating bone loss in an ovariectomy model
    Cho, Chang-Young
    Kang, Se Hwang
    Kim, Byung-Chan
    Kim, Tae-Kyu
    Kim, Jae-Hyun
    Kim, Minsun
    Sohn, Youngjoo
    Jung, Hyuk-Sang
    MOLECULAR MEDICINE REPORTS, 2023, 28 (04)
  • [25] Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression
    Han, Sang-Yong
    Kim, Yun-Kyung
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2019, 47 (02): : 439 - 455
  • [26] Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway
    Li, Liang
    Sapkota, Mahesh
    Gao, Ming
    Choi, Hyukjae
    Soh, Yunjo
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 815 : 202 - 209
  • [27] Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1
    Zhu, Xiaoqing
    Zhao, Yinghua
    Jiang, Yuxue
    Qin, Tianxue
    Chen, Jintong
    Chu, Xiao
    Yi, Qing
    Gao, Sujun
    Wang, Siqing
    ONCOTARGET, 2017, 8 (32): : 53366 - 53374
  • [28] Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
    Wang, Lu
    Chen, Kai
    He, Jianbo
    Kenny, Jacob
    Yuan, Yu
    Chen, Junhao
    Liu, Qian
    Tan, Renxiang
    Zhao, Jinmin
    Xu, Jiake
    RSC ADVANCES, 2019, 9 (66) : 38438 - 38446
  • [29] Antioxidant enzyme Prdx1 inhibits osteoclastogenesis via suppressing ROS and NFATc1 signaling pathways
    Wang, Chao
    Wang, Gang
    Song, Fangming
    Zhao, Jinmin
    Liu, Qian
    Xu, Jiake
    JOURNAL OF CELLULAR PHYSIOLOGY, 2024, 239 (12)
  • [30] Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression
    Yoon-Hee Cheon
    Jong Min Baek
    Sun-Hyang Park
    Sung-Jun Ahn
    Myeung Su Lee
    Jaemin Oh
    Ju-Young Kim
    BMC Complementary and Alternative Medicine, 15